profit from every $100 of sales.
$0$100
MaxCyte
$1.13-13.08% today
-23.1% in 1 year
1-year low $0.681-year high $1.76
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What MaxCyte sold, what it kept, and what it did with the cash.
Sales went from $44.3 million in 2022 to $33.0 million in 2025, with -$44.6 million of profit last year.
SalesProfit
MaxCyte vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| MaxCyte | No profit yet | ||
 Boston Scientific | 22.4× · Fair price | ||
 Koninklijke Philips | 29.7× · Fair price | ||
 Steris | 31.9× · Expensive | ||
 Zimmer Biomet Holdings | 28.8× · Fair price |
AI analysis
An AI analyst reads MaxCyte's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 44 | 41 | 39 | 33 | |
| 39 | 37 | 32 | 27 | |
| -27 | -48 | -51 | -45 | |
| -25 | -44 | -46 | -40 | |
| -24 | -38 | -41 | -45 | |
| -0.23 | -0.37 | -0.39 | -0.42 | |
| 88.5% | 88.5% | 81.6% | 81.2% | |
| -61.8% | -117.0% | -132.5% | -137.1% | |
| -53.3% | -91.8% | -106.3% | -135.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 287 | 268 | 239 | 203 |
| Cash | 11 | 47 | 28 | 20 |
| Total debt | 16 | 19 | 18 | 18 |
| Total liabilities | 33 | 36 | 33 | 31 |
| 254 | 232 | 206 | 171 | |
| 102 | 103 | 105 | 106 | |
| -8.0% | -15.2% | -18.0% | -18.9% | |
| -9.3% | -16.3% | -19.9% | -26.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -15 | -22 | -28 | -34 | |
| 18 | 4 | 2 | 2 | |
| -33 | -25 | -29 | -36 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 12 | 14 | 13 | 9 |
Valuation
- –
- –
- –
- 0.7×
- 3.5×
- –
- –
- -31.0%
- -38.3%
- 0.0%
Profitability
- 81.2%
- -137.1%
- -135.1%
- -111.6%
- -20.8%
- -14.6%
- -22.0%
- -20.1%
- -21.0%
- 58.2%
Growth
- −9.3%
- –
- −23.6%
- –
- +4.1%
Financial health
- -0.1×
- 0.10
- 9.0%
- –
- 12.04
- 11.29
- 0.17
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 953
Bottom 2%of 877
Bottom 8%of 871
Bottom 2%of 988
What analysts expect
- Average price target
- $6.00
- Range
- $6.00 – $6.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.04 | -0.10 | +60.0% |
| Mar 24, 2026 | -0.06 | -0.08 | +25.0% |
| Nov 12, 2025 | -0.12 | -0.11 | −9.1% |
| Aug 6, 2025 | -0.12 | -0.10 | −20.0% |
| May 7, 2025 | -0.10 | -0.10 | +0.0% |
| Mar 11, 2025 | -0.10 | -0.12 | +16.7% |
| Nov 6, 2024 | -0.11 | -0.13 | +15.4% |
| Aug 6, 2024 | -0.09 | -0.14 | +35.7% |
News
MaxCyte falls after $151.8M deal to buy Akron Bio for cash and stockSeeking Alpha · Nov 10, 2026MaxCyte stock rallies on initial Q3 revenue, higher FY26 outlookSeeking Alpha · Oct 14, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
72Pass
Philip Fisher
44No pass
Peter Lynch
30No pass
Joel Greenblatt
2No pass
Charlie Munger
38No pass
Terry Smith
36No pass
Questions about MaxCyte
Is MaxCyte a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the MaxCyte AI analysis
What does MaxCyte do?
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. It is in Medical - Devices.
Does MaxCyte pay a dividend?
No. MaxCyte does not pay a dividend at the moment.
Is MaxCyte stock halal?
Questionable. MaxCyte sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has MaxCyte stock done over the past year?
Down 23.1% over the past twelve months, to $1.13. It traded between $0.68 and $1.76 and is 35.8% below its high.
Who are MaxCyte's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with MaxCyte's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.